302 related articles for article (PubMed ID: 28648618)
1. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X; Spano JP; Espie M; Cottu P; Jouannaud C; Pottier V; Moreau L; Extra JM; Lortholary A; Rivera P; Spaeth D; Attar-Rabia H; Benkanoun C; Dima-Martinez L; Esposito N; Gligorov J
Eur J Cancer; 2017 Sep; 82():230-236. PubMed ID: 28648618
[TBL] [Abstract][Full Text] [Related]
2. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
[TBL] [Abstract][Full Text] [Related]
3. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.
Pivot X; Gligorov J; Müller V; Curigliano G; Knoop A; Verma S; Jenkins V; Scotto N; Osborne S; Fallowfield L;
Ann Oncol; 2014 Oct; 25(10):1979-1987. PubMed ID: 25070545
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.
Jackisch C; Kim SB; Semiglazov V; Melichar B; Pivot X; Hillenbach C; Stroyakovskiy D; Lum BL; Elliott R; Weber HA; Ismael G
Ann Oncol; 2015 Feb; 26(2):320-5. PubMed ID: 25403587
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.
Pivot X; Verma S; Fallowfield L; Müller V; Lichinitser M; Jenkins V; Sánchez Muñoz A; Machackova Z; Osborne S; Gligorov J;
Eur J Cancer; 2017 Nov; 86():82-90. PubMed ID: 28963915
[TBL] [Abstract][Full Text] [Related]
6. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
[TBL] [Abstract][Full Text] [Related]
7. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).
Ciruelos EM; Montaño A; Rodríguez CA; González-Flores E; Lluch A; Garrigós L; Quiroga V; Antón A; Malón D; Chacón JI; Velasco M; Gonzalez-Cortijo L; Jolis L; Echarri MJ; Muñoz M; Pascual T; Amigo Y; Casas M; Carrasco E; Casas A
Eur J Cancer Care (Engl); 2020 Jul; 29(4):e13253. PubMed ID: 32578279
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
Ismael G; Hegg R; Muehlbauer S; Heinzmann D; Lum B; Kim SB; Pienkowski T; Lichinitser M; Semiglazov V; Melichar B; Jackisch C
Lancet Oncol; 2012 Sep; 13(9):869-78. PubMed ID: 22884505
[TBL] [Abstract][Full Text] [Related]
9. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.
Gligorov J; Curigliano G; Müller V; Knoop A; Jenkins V; Verma S; Osborne S; Lauer S; Machackova Z; Fallowfield L; Pivot X
Breast; 2017 Aug; 34():89-95. PubMed ID: 28549309
[TBL] [Abstract][Full Text] [Related]
10. Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Pivot X; Spano JP; Espie M; Jouannaud C; Pottier V; Moreau L; Extra JM; Lortholary A; Rivera P; Spaeth D; Mouri Z; Tariket F; Dupin J; Berthois A; Ionescu-Goga M; Ferhat A; Cottu P; Gligorov J
Clin Breast Cancer; 2023 Oct; 23(7):e412-e419. PubMed ID: 37423801
[TBL] [Abstract][Full Text] [Related]
11. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Jackisch C; Hegg R; Stroyakovskiy D; Ahn JS; Melichar B; Chen SC; Kim SB; Lichinitser M; Starosławska E; Kunz G; Falcon S; Chen ST; Crepelle-Fléchais A; Heinzmann D; Shing M; Pivot X
Eur J Cancer; 2016 Jul; 62():62-75. PubMed ID: 27208905
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J; Ataseven B; Verrill M; De Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X;
Eur J Cancer; 2017 Sep; 82():237-246. PubMed ID: 28625777
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous Trastuzumab: A Review in HER2-Positive Breast Cancer.
Heo YA; Syed YY
Target Oncol; 2019 Dec; 14(6):749-758. PubMed ID: 31686307
[TBL] [Abstract][Full Text] [Related]
14. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.
De Cock E; Pivot X; Hauser N; Verma S; Kritikou P; Millar D; Knoop A
Cancer Med; 2016 Mar; 5(3):389-97. PubMed ID: 26806010
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer.
Denys H; Martinez-Mena CL; Martens MT; D'Hondt RG; Graas ML; Evron E; Fried G; Ben-Baruch NE; Vulsteke C; Van Steenberghe MM
Breast Cancer Res Treat; 2020 May; 181(1):97-105. PubMed ID: 32240454
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Reinisch M; Untch M; Mahlberg R; Reimer T; Hitschold T; Marmé F; Aydogdu M; Schmatloch S; Lück HJ; Schmidt M; Ladda E; Sinn BV; Klare P; Janni W; Jackisch C; Denkert C; Seiler S; Göhler T; Michel L; Burchardi N; Stickeler E; Rey J; Klutinus N; Möbus V; Loibl S
Breast; 2022 Dec; 66():110-117. PubMed ID: 36223695
[TBL] [Abstract][Full Text] [Related]
17. Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study.
Fallowfield L; Osborne S; Langridge C; Monson K; Kilkerr J; Jenkins V
Breast; 2015 Apr; 24(2):166-70. PubMed ID: 25623753
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use.
Lazaro Cebas A; Cortijo Cascajares S; Pablos Bravo S; Del Puy Goyache Goñi M; Gonzalez Monterrubio G; Perez Cardenas MD; Ferrari Piquero JM
J BUON; 2017; 22(2):334-339. PubMed ID: 28534353
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer.
Sanford M
Target Oncol; 2014 Mar; 9(1):85-94. PubMed ID: 24664187
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
Stefanou D; Kokkali S; Tripodaki ES; Drizou M; Magou E; Zylis D; Prevezanou M; Kapiris M; Nasi D; Ntokou A; Dede M; Ardavanis A
Anticancer Res; 2018 Nov; 38(11):6565-6569. PubMed ID: 30396987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
